Daily electronic self-monitoring in bipolar disorder using smartphones - the MONARCA I trial: a randomized, placebo-controlled, single-blind, parallel group trial

被引:119
|
作者
Faurholt-Jepsen, M. [1 ]
Frost, M. [2 ]
Ritz, C. [3 ]
Christensen, E. M. [1 ]
Jacoby, A. S. [1 ]
Mikkelsen, R. L. [1 ]
Knorr, U. [1 ]
Bardram, J. E. [2 ]
Vinberg, M. [1 ]
Kessing, L. V. [1 ]
机构
[1] Rigshosp, Psychiat Ctr Copenhagen, Copenhagen Clin Affect Disorder, DK-2100 Copenhagen, Denmark
[2] IT Univ Copenhagen, Pervas Interact Lab PIT Lab, Copenhagen, Denmark
[3] Univ Copenhagen, Fac Life Sci, Dept Basic Sci & Environm, Copenhagen, Denmark
关键词
Bipolar disorder; electronic self-monitoring; feedback loop; randomized controlled trial; smartphone; the MONARCA I trial; MAJOR DEPRESSION INVENTORY; LONGITUDINAL COURSE; COGNITIVE IMPAIRMENT; MOOD INSTABILITY; SYMPTOMS; VALIDITY; SCALE; RELIABILITY; MANIA; INTERVENTIONS;
D O I
10.1017/S0033291715000410
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background. The number of studies on electronic self-monitoring in affective disorder and other psychiatric disorders is increasing and indicates high patient acceptance and adherence. Nevertheless, the effect of electronic self-monitoring in patients with bipolar disorder has never been investigated in a randomized controlled trial (RCT). The objective of this trial was to investigate in a RCT whether the use of daily electronic self-monitoring using smartphones reduces depressive and manic symptoms in patients with bipolar disorder. Method. A total of 78 patients with bipolar disorder according to ICD-10 criteria, aged 18-60 years, and with 17-item Hamilton Depression Rating Scale (HAMD-17) and Young Mania Rating Scale (YMRS) scores <= 17 were randomized to the use of a smartphone for daily self-monitoring including a clinical feedback loop (the intervention group) or to the use of a smartphone for normal communicative purposes (the control group) for 6 months. The primary outcomes were differences in depressive and manic symptoms measured using HAMD-17 and YMRS, respectively, between the intervention and control groups. Results. Intention-to-treat analyses using linear mixed models showed no significant effects of daily self-monitoring using smartphones on depressive as well as manic symptoms. There was a tendency towards more sustained depressive symptoms in the intervention group (B = 2.02, 95% confidence interval -0.13 to 4.17, p = 0.066). Sub-group analysis among patients without mixed symptoms and patients with presence of depressive and manic symptoms showed significantly more depressive symptoms and fewer manic symptoms during the trial period in the intervention group. Conclusions. These results highlight that electronic self-monitoring, although intuitive and appealing, needs critical consideration and further clarification before it is implemented as a clinical tool.
引用
收藏
页码:2691 / 2704
页数:14
相关论文
共 50 条
  • [31] Engagement Strategies for Self-Monitoring Symptoms of Bipolar Disorder With Mobile and Wearable Technology: Protocol for a Randomized Controlled Trial
    Cochran, Amy
    Belman-Wells, Livia
    McInnis, Melvin
    JMIR RESEARCH PROTOCOLS, 2018, 7 (05):
  • [32] Evaluation of cariprazine in the treatment of bipolar I and II depression: a randomized, double-blind, placebo-controlled, phase 2 trial
    Yatham, Lakshmi N.
    Vieta, Eduard
    Earley, Willie
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2020, 35 (03) : 147 - 156
  • [33] Varenicline and counseling for vaping cessation: a double-blind, randomized, parallel-group, placebo-controlled trial
    Pasquale Caponnetto
    Davide Campagna
    Jasjit S. Ahluwalia
    Christopher Russell
    Marilena Maglia
    Paolo Marco Riela
    Carmelo Fabio Longo
    Barbara Busa
    Riccardo Polosa
    BMC Medicine, 21
  • [34] Varenicline and counseling for vaping cessation: a double-blind, randomized, parallel-group, placebo-controlled trial
    Caponnetto, Pasquale
    Campagna, Davide
    Ahluwalia, Jasjit S.
    Russell, Christopher
    Maglia, Marilena
    Riela, Paolo Marco
    Longo, Carmelo Fabio
    Busa, Barbara
    Polosa, Riccardo
    BMC MEDICINE, 2023, 21 (01)
  • [35] Dry-needling and exercise for chronic whiplash-associated disorders: a randomized single-blind placebo-controlled trial
    Sterling, Michele
    Vicenzino, Bill
    Souvlis, Tina
    Connelly, Luke B.
    PAIN, 2015, 156 (04) : 635 - 643
  • [36] A randomized, double-blind, placebo-controlled clinical trial of acamprosate in alcohol-dependent individuals with bipolar disorder: a preliminary report
    Tolliver, Bryan K.
    DeSantis, Stacia M.
    Brown, Delisa G.
    Prisciandaro, James J.
    Brady, Kathleen T.
    BIPOLAR DISORDERS, 2012, 14 (01) : 54 - 63
  • [37] N-acetyl cysteine for depressive symptoms in bipolar disorder - A double-blind randomized placebo-controlled trial
    Berk, Michael
    Copolov, David L.
    Dean, Olivia
    Lu, Kristy
    Jeavons, Sue
    Schapkaitz, Ian
    Anderson-Hunt, Murray
    Bush, Ashley I.
    BIOLOGICAL PSYCHIATRY, 2008, 64 (06) : 468 - 475
  • [38] Ziprasidone Plus a Mood Stabilizer in Subjects With Bipolar I Disorder: A 6-Month, Randomized, Placebo-Controlled, Double-Blind Trial
    Bowden, Charles L.
    Vieta, Eduard
    Ice, Kathleen S.
    Schwartz, Jeffrey H.
    Wang, Paul P.
    Versavel, Mark
    JOURNAL OF CLINICAL PSYCHIATRY, 2010, 71 (02) : 130 - 137
  • [39] A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, TWO-SITE CLINICAL TRIAL OF PREGNENOLONE OR CITICOLINE IN PEOPLE WITH BIPOLAR DISORDERS AND ALCOHOL USE DISORDER
    Brown, E. Sherwood
    Palka, Jayme
    Holmes, Traci
    Durand, Dante
    Salloum, Ihsan
    NEUROPSYCHOPHARMACOLOGY, 2024, 49 : 273 - 273
  • [40] A Prospective, Single-Blind, Placebo-Controlled Trial of Bone Marrow Aspirate Concentrate for Knee Osteoarthritis
    Shapiro, Shane A.
    Kazmerchak, Shari E.
    Heckman, Michael G.
    Zubair, Abba C.
    O'Connor, Mary I.
    AMERICAN JOURNAL OF SPORTS MEDICINE, 2017, 45 (01) : 82 - 90